Tourmaline Bio Unveils Promising Phase 2 Trial Data for Pacibekitug at European Society of Cardiology Congress 2025

Reuters

2025/08/31

<a href="https://laohu8.com/S/TRML">Tourmaline Bio</a> Unveils Promising Phase 2 Trial Data for Pacibekitug at European Society of Cardiology Congress 2025

Tourmaline Bio, Inc. (NASDAQ: TRML), a late-stage clinical biotechnology company, has presented new data from its ongoing Phase 2 TRANQUILITY trial of pacibekitug at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The presentation highlighted the drug's ability to consistently reduce high-sensitivity C-reactive protein (hs-CRP) across a broad range of subgroups. Additionally, the study reported statistically significant reductions in secondary pharmacodynamic biomarkers associated with IL-6 pathway activity, including lipoprotein(a), fibrinogen, and serum amyloid A. The trial is a randomized, placebo-controlled study evaluating pacibekitug, a long-acting anti-IL-6 monoclonal antibody, in patients with elevated hs-CRP and chronic kidney disease. The results were previously summarized in a May 2025 press release by Tourmaline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tourmaline Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521017-en) on August 31, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2563856252"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563856252\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563856252?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-31 22:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563856252","market":"us","top_or_hot":-1,"title":"Tourmaline Bio Unveils Promising Phase 2 Trial Data for Pacibekitug at European Society of Cardiology Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TRML\">Tourmaline Bio</a> Unveils Promising Phase 2 Trial Data for Pacibekitug at European Society of Cardiology Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tourmaline Bio, Inc. (NASDAQ: TRML), a late-stage clinical biotechnology company, has presented new data from its ongoing Phase 2 TRANQUILITY trial of pacibekitug at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The presentation highlighted the drug's ability to consistently reduce high-sensitivity C-reactive protein (hs-CRP) across a broad range of subgroups. Additionally, the study reported statistically significant reductions in secondary pharmacodynamic biomarkers associated with IL-6 pathway activity, including lipoprotein(a), fibrinogen, and serum amyloid A. The trial is a randomized, placebo-controlled study evaluating pacibekitug, a long-acting anti-IL-6 monoclonal antibody, in patients with elevated hs-CRP and chronic kidney disease. The results were previously summarized in a May 2025 press release by Tourmaline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tourmaline Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521017-en) on August 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tourmaline Bio Unveils Promising Phase 2 Trial Data for Pacibekitug at European Society of Cardiology Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTourmaline Bio Unveils Promising Phase 2 Trial Data for Pacibekitug at European Society of Cardiology Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-31 22:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TRML\">Tourmaline Bio</a> Unveils Promising Phase 2 Trial Data for Pacibekitug at European Society of Cardiology Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tourmaline Bio, Inc. (NASDAQ: TRML), a late-stage clinical biotechnology company, has presented new data from its ongoing Phase 2 TRANQUILITY trial of pacibekitug at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The presentation highlighted the drug's ability to consistently reduce high-sensitivity C-reactive protein (hs-CRP) across a broad range of subgroups. Additionally, the study reported statistically significant reductions in secondary pharmacodynamic biomarkers associated with IL-6 pathway activity, including lipoprotein(a), fibrinogen, and serum amyloid A. The trial is a randomized, placebo-controlled study evaluating pacibekitug, a long-acting anti-IL-6 monoclonal antibody, in patients with elevated hs-CRP and chronic kidney disease. The results were previously summarized in a May 2025 press release by Tourmaline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tourmaline Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521017-en) on August 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250831:nNDL2RzKCk:1","article_id":"2563856252","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563856252","pubTimestamp":1756650243,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tourmaline Bio, Inc. , a late-stage clinical biotechnology company, has presented new data from its ongoing Phase 2 TRANQUILITY trial of pacibekitug at the European Society of Cardiology  Congress 2025 in Madrid, Spain. The presentation highlighted the drug's ability to consistently reduce high-sensitivity C-reactive protein  across a broad range of subgroups. Additionally, the study reported statistically significant reductions in secondary pharmacodynamic biomarkers associated with IL-6 pathway activity, including lipoprotein, fibrinogen, and serum amyloid A. The trial is a randomized, placebo-controlled study evaluating pacibekitug, a long-acting anti-IL-6 monoclonal antibody, in patients with elevated hs-CRP and chronic kidney disease. The results were previously summarized in a May 2025 press release by Tourmaline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","TRML":"Tourmaline Bio","BK4139":"生物科技"},"translate_title":"Tourmaline Bio在2025年欧洲心脏病学会大会上公布了Pacibekitug有希望的2期试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRML":0.9},"content_text":"Tourmaline Bio Unveils Promising Phase 2 Trial Data for Pacibekitug at European Society of Cardiology Congress 2025\n    \n\n        Tourmaline Bio, Inc. (NASDAQ: TRML), a late-stage clinical biotechnology company, has presented new data from its ongoing Phase 2 TRANQUILITY trial of pacibekitug at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The presentation highlighted the drug's ability to consistently reduce high-sensitivity C-reactive protein (hs-CRP) across a broad range of subgroups. Additionally, the study reported statistically significant reductions in secondary pharmacodynamic biomarkers associated with IL-6 pathway activity, including lipoprotein(a), fibrinogen, and serum amyloid A. The trial is a randomized, placebo-controlled study evaluating pacibekitug, a long-acting anti-IL-6 monoclonal antibody, in patients with elevated hs-CRP and chronic kidney disease. The results were previously summarized in a May 2025 press release by Tourmaline.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tourmaline Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521017-en) on August 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}